These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
548 related articles for article (PubMed ID: 23433960)
1. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Macchioni P; Boiardi L; Catanoso M; Pulsatelli L; Pipitone N; Meliconi R; Salvarani C Semin Arthritis Rheum; 2013 Aug; 43(1):113-8. PubMed ID: 23433960 [TBL] [Abstract][Full Text] [Related]
2. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883 [TBL] [Abstract][Full Text] [Related]
3. Effective control of polymyalgia rheumatica with tocilizumab. Al Rashidi A; Hegazi MO; Mohammad SA; Varghese A J Clin Rheumatol; 2013 Oct; 19(7):400-1. PubMed ID: 24048113 [TBL] [Abstract][Full Text] [Related]
4. Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica. Lally L; Forbess L; Hatzis C; Spiera R Arthritis Rheumatol; 2016 Oct; 68(10):2550-4. PubMed ID: 27159185 [TBL] [Abstract][Full Text] [Related]
5. Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review. Sakai R; Kondo T; Kurasawa T; Nishi E; Okuyama A; Chino K; Shibata A; Okada Y; Takei H; Nagasawa H; Amano K Clin Rheumatol; 2017 Oct; 36(10):2383-2392. PubMed ID: 28733791 [TBL] [Abstract][Full Text] [Related]
6. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. Palard-Novello X; Querellou S; Gouillou M; Saraux A; Marhadour T; Garrigues F; Abgral R; Salaün PY; Devauchelle-Pensec V Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):773-9. PubMed ID: 26753600 [TBL] [Abstract][Full Text] [Related]
8. Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition. Camellino D; Soldano S; Cutolo M; Cimmino MA Rheumatol Int; 2018 Sep; 38(9):1699-1704. PubMed ID: 29946742 [TBL] [Abstract][Full Text] [Related]
9. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Spiera R; Unizony SH; Bao M; Luder Y; Han J; Pavlov A; Stone JH Semin Arthritis Rheum; 2021 Apr; 51(2):469-476. PubMed ID: 33784598 [TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Mori S; Koga Y Clin Rheumatol; 2016 May; 35(5):1367-75. PubMed ID: 24803231 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study. Assaraf M; Chevet B; Wendling D; Philippe P; Cailliau E; Roux C; Dieude P; Ottaviani S; Avouac J; Delacour M; Houvenagel E; Sellam J; Cortet B; Henry J; Flipo RM; Devauchelle-Pensec V Rheumatology (Oxford); 2024 Aug; 63(8):2065-2073. PubMed ID: 37603729 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Devauchelle-Pensec V; Berthelot JM; Cornec D; Renaudineau Y; Marhadour T; Jousse-Joulin S; Querellou S; Garrigues F; De Bandt M; Gouillou M; Saraux A Ann Rheum Dis; 2016 Aug; 75(8):1506-10. PubMed ID: 26929219 [TBL] [Abstract][Full Text] [Related]